Date：23 July (Friday) 10:40 – 12:10 (GMT+8)
Venue：www.bioasiataiwan.com / Online event platform
While only a handful have been approved, the cell and gene therapy product pipeline is bursting with more than 1,200 therapies, more than half in Phase 2 trials. Sales growth estimates of 15% for cell therapies and 30% for gene therapies are indicative of the enormous potential of this sector, with Asian labs and biotechs well placed to participate. In this session we've gathered world-leading experts from across big pharma, biotech, academia and regulatory to examine the current cell and gene therapy landscape, with important discussions lined up on challenges, opportunities and essential development strategies.